Drugs / human Bone Marrow Mesenchymal Stem Cell
human Bone Marrow Mesenchymal Stem Cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06111846 | Dec 2023 → Jul 2025 overdue | autoimmune pulmonary alveolar proteinosis | Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human Bone Marrow Mesenchymal Stem Cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06111846 ↗ |
| Modality | Cell therapy | “human Bone Marrow Mesenchymal Stem Cell (hBMMSC)” NCT06111846 ↗ |
| Route | Intravenous | “hBMMSC intravenous treatment” NCT06111846 ↗ |